ARCHIVES

Pfizer’s Inlyta Gives FDA a Teaching Moment: Not All PFS Advantages Are Created Equal

This article is from The Cancer Letter archive.

Vol. 37 No. 46 | December 16, 2011

Download PDF Visit The Full Archive

Related Articles

High-Dose Chemo, Stem Cell Transplant No Benefit For Node+ Breast Cancer

January 25, 2008

Mihich Recommendation for Antigen Development In BRMP Summarized

December 14, 1979

Senate Approves $47 Million For More AIDs Drugs

September 19, 1986

DCT Contract Funds To Be 20 Percent less In FY 1986 Than In 1985; To Eliminate ‘Low Priority’ Contracts

February 14, 1986

DeVita Emphasizes NCI Prevention In Statement To Senate Committee

February 15, 1980

Intramural AIDS Vaccine Research Center In Development By NCI, NIAID Scientists

June 13, 1997